MedTrace Logo

Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects

NCT00255138 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-04-01

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effectiveness and safety of atomoxetine in enhancing attention and concentration among childhood survivors of cancer.

Conditions

  • Cancer
  • Cognitive Late Effects

Interventions

DRUG

Atomoxetine

Sponsors & Collaborators

Principal Investigators

  • Ronald T Brown, Ph.D. · Temple University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255138 on ClinicalTrials.gov